RT Journal Article
SR Electronic
T1 Changes in the Circulating Plasma Levels of VEGF and VEGF-D after Adjuvant Chemotherapy in Patients with Breast Cancer and 1 to 3 Positive Lymph Nodes
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1719
OP 1726
VO 26
IS 2C
A1 KÜMMEL, SHERKO
A1 EGGEMANN, HOLM
A1 LÜFTNER, DIANA
A1 THOMAS, ANKE
A1 JESCHKE, SOPHIA
A1 ZERFEL, NADINE
A1 HEILMANN, VOLKER
A1 EMONS, GÜNTER
A1 ZEISER, TOBIAS
A1 ULM, KURT
A1 KOBL, MICHAEL
A1 KORLACH, SUSANNE
A1 SCHMID, PETER
A1 SEHOULI, JALID
A1 ELLING, DIRK
A1 BLOHMER, JENS-UWE
YR 2006
UL http://ar.iiarjournals.org/content/26/2C/1719.abstract
AB Background: The goal of the present study was to investigate the changes in concentration of the important lymph-angiogenesis factors vascular endothelium-derived growth factor (VEGF) and VEGF-D under adjuvant chemotherapy. Materials and Methods: The blood plasma of a total of 142 patients with breast carcinoma and with 1 to 3 affected lymph nodes was investigated, using the quantitative sandwich enzyme immunoassay technique, prior to and following chemotherapy, within the framework of a randomized phase III study: the patients received either conventional or dose-intensified chemotherapy. Results: In general, there was a significant reduction in VEGF levels after chemotherapy only in patients with large tumors (T3) (p=0.043). There was also an almost significant reduction in patients with an overexpression of c-erbB-2 (Dako Score +3, p=0.052). In contrast, the clearest reduction in VEGF-D occurred in patients with a positive hormone receptor status (p=0.04) or in patients with a low expression of c-erbB-2 (Dako Score +1, p=0.05). A significant effect of chemotherapy on VEGF-D was determined only in patients who had a baseline level that was above the normal (conventionel treatment p=0.005; dose-intensified treatment p=0.004). Conclusion: Both VEGF and VEGF-D levels changed after chemotherapy, depending on the patient and tumor characteristics. With respect to changes in the plasma levels of VEGF and VEGF-D, there were no significant differences between dose-intensified and conventional chemotherapy. Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved